Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

Salvatore D’Angelo,1 Giuseppina Tramontano,1 Michele Gilio,1 Pietro Leccese,1 Ignazio Olivieri1,2 1Rheumatology Institute of Lucania (IRel) - Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, 2Basilicata Ricer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	D'Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Psoriatic arthritis treatment biologic drugs TNF inhibitors ustekinumab secukinumab Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/2f583fd1e7ab4b059234f1b123310e4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f583fd1e7ab4b059234f1b123310e4a
record_format	dspace
spelling	oai:doaj.org-article:2f583fd1e7ab4b059234f1b123310e4a2021-12-02T07:22:53ZReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders1179-156Xhttps://doaj.org/article/2f583fd1e7ab4b059234f1b123310e4a2017-03-01T00:00:00Zhttps://www.dovepress.com/review-of-the-treatment-of-psoriatic-arthritis-with-biological-agents--peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XSalvatore D’Angelo,1 Giuseppina Tramontano,1 Michele Gilio,1 Pietro Leccese,1 Ignazio Olivieri1,2 1Rheumatology Institute of Lucania (IRel) - Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, 2Basilicata Ricerca Biomedica (BRB) Foundation, Potenza, Italy Abstract: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary approach. The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA. No evidence-based strategies are currently available for guiding the rheumatologist to prescribe biological drugs. Several international and national recommendation sets are currently available with the aim to help rheumatologists in everyday clinical practice management of PsA patients treated with biological therapy. Since no specific biological agent has been demonstrated to be more effective than others, the drug choice should be made according to the available safety data, the presence of extra-articular manifestations, the patient’s preferences (e.g., administration route), and the drug price. However, future studies directly comparing different biological drugs and assessing the efficacy of treatment strategies specific for PsA are urgently needed. Keywords: psoriatic arthritis, treatment, biological drugs, TNF inhibitors, ustekinumab, secukinumabD'Angelo STramontano GGilio MLeccese POlivieri IDove Medical PressarticlePsoriatic arthritistreatmentbiologic drugsTNF inhibitorsustekinumabsecukinumabDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 9, Pp 21-28 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psoriatic arthritis treatment biologic drugs TNF inhibitors ustekinumab secukinumab Diseases of the musculoskeletal system RC925-935
spellingShingle	Psoriatic arthritis treatment biologic drugs TNF inhibitors ustekinumab secukinumab Diseases of the musculoskeletal system RC925-935 D'Angelo S Tramontano G Gilio M Leccese P Olivieri I Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
description	Salvatore D’Angelo,1 Giuseppina Tramontano,1 Michele Gilio,1 Pietro Leccese,1 Ignazio Olivieri1,2 1Rheumatology Institute of Lucania (IRel) - Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, 2Basilicata Ricerca Biomedica (BRB) Foundation, Potenza, Italy Abstract: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary approach. The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA. No evidence-based strategies are currently available for guiding the rheumatologist to prescribe biological drugs. Several international and national recommendation sets are currently available with the aim to help rheumatologists in everyday clinical practice management of PsA patients treated with biological therapy. Since no specific biological agent has been demonstrated to be more effective than others, the drug choice should be made according to the available safety data, the presence of extra-articular manifestations, the patient’s preferences (e.g., administration route), and the drug price. However, future studies directly comparing different biological drugs and assessing the efficacy of treatment strategies specific for PsA are urgently needed. Keywords: psoriatic arthritis, treatment, biological drugs, TNF inhibitors, ustekinumab, secukinumab
format	article
author	D'Angelo S Tramontano G Gilio M Leccese P Olivieri I
author_facet	D'Angelo S Tramontano G Gilio M Leccese P Olivieri I
author_sort	D'Angelo S
title	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
title_short	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
title_full	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
title_fullStr	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
title_full_unstemmed	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
title_sort	review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/2f583fd1e7ab4b059234f1b123310e4a
work_keys_str_mv	AT dangelos reviewofthetreatmentofpsoriaticarthritiswithbiologicalagentschoiceofdrugforinitialtherapyandswitchtherapyfornonresponders AT tramontanog reviewofthetreatmentofpsoriaticarthritiswithbiologicalagentschoiceofdrugforinitialtherapyandswitchtherapyfornonresponders AT giliom reviewofthetreatmentofpsoriaticarthritiswithbiologicalagentschoiceofdrugforinitialtherapyandswitchtherapyfornonresponders AT leccesep reviewofthetreatmentofpsoriaticarthritiswithbiologicalagentschoiceofdrugforinitialtherapyandswitchtherapyfornonresponders AT olivierii reviewofthetreatmentofpsoriaticarthritiswithbiologicalagentschoiceofdrugforinitialtherapyandswitchtherapyfornonresponders
_version_	1718399448219910144

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

Ejemplares similares